Current Report Filing (8-k)
October 11 2016 - 4:48PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): October 4, 2016
Cynapsus
Therapeutics Inc.
(Exact name of registrant as specified in
its charter)
Canada
|
001-37426
|
98-1226819
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
828 Richmond Street West,
Toronto, Ontario, Canada
(Address of principal executive offices)
|
M6J 1C9
(Zip Code)
|
Registrant’s telephone number, including
area code:
416-703-2449
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 3.02 Unregistered
Sales of Equity Securities.
From
September 20, 2016 to October 11, 2016, Cynapsus Therapeutics Inc. (the “Company”) issued an aggregate of 249,254
common shares pursuant to the exercise of warrants, for aggregate cash consideration of approximately Cdn$3,221,029. Such common
shares were issued by the Company in the United States and to “U.S. persons” (as both such terms are defined in Regulation
S (“Regulation S”) under the United States Securities Act of 1933, as amended (the “Securities Act”)),
in reliance upon Rule 506(b) of Regulation D under the Securities Act (“Regulation D”), solely to “accredited
investors,” as such term is defined in Rule 501(a) of Regulation D. Such common shares were issued outside the United States
to non-U.S. persons in reliance upon
Regulation S.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
CYNAPSUS THERAPEUTICS INC.
|
|
|
|
|
Date: October 11, 2016
|
By:
|
/s/ Andrew Williams
|
|
Name:
|
Andrew Williams
|
|
Title:
|
Chief Operating Officer and Chief Financial Officer
|
|
|
|
Cynapsus Therapeutics Inc. (NASDAQ:CYNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cynapsus Therapeutics Inc. (NASDAQ:CYNA)
Historical Stock Chart
From Apr 2023 to Apr 2024